Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Minglei Yang, Jian Zhao, Tielong Liu, Xinghai Yang, Haifeng Wei, Wei Xu & Jianru Xiao. (2018) Use of FLT3 inhibitors in acute myeloid leukemia remission induction or salvage therapy: systematic review and meta-analysis. Cancer Management and Research 10, pages 2635-2652.
Read now
Read now
Naveen Pemmaraju, Hagop Kantarjian, Michael Andreeff, Jorge Cortes & Farhad Ravandi. (2014) Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia. Expert Opinion on Investigational Drugs 23:7, pages 943-954.
Read now
Read now
Articles from other publishers (18)
Nichole Sly & Katie Gaspar. (2019) Midostaurin for the management of FLT3-mutated acute myeloid leukemia and advanced systemic mastocytosis. American Journal of Health-System Pharmacy 76:5, pages 268-274.
Crossref
Crossref
Rocio I.R. Macias, Anabel Sánchez-Martín, Gabriela Rodríguez-Macías, Luis I. Sánchez-Abarca, Elisa Lozano, Elisa Herraez, Maria D. Odero, José L. Díez-Martín, Jose J.G. Marin & Oscar Briz. (2018) Role of drug transporters in the sensitivity of acute myeloid leukemia to sorafenib. Oncotarget 9:47, pages 28474-28485.
Crossref
Crossref
Stephan Metzelder & Christoph Röllig. (2018) FLT3-Inhibitoren in der Therapie der akuten myeloischen LeukämieFLT3 inhibitors for the treatment of acute myeloid leukemia. best practice onkologie 13:4, pages 182-190.
Crossref
Crossref
Philipp G. Hemmati, Lam G. Vuong, Theis H. Terwey, Christian F. Jehn, Philipp le Coutre, Olaf Penack, Il-Kang Na, Bernd Dörken & Renate Arnold. (2017) Predictive significance of the European LeukemiaNet classification of genetic aberrations in patients with acute myeloid leukaemia undergoing allogeneic stem cell transplantation. European Journal of Haematology 98:2, pages 160-168.
Crossref
Crossref
Gevorg Tamamyan, Tapan Kadia, Farhad Ravandi, Gautam Borthakur, Jorge Cortes, Elias Jabbour, Naval Daver, Maro Ohanian, Hagop Kantarjian & Marina Konopleva. (2017) Frontline treatment of acute myeloid leukemia in adults. Critical Reviews in Oncology/Hematology 110, pages 20-34.
Crossref
Crossref
Maximilian Fleischmann, Ulf Schnetzke, Karin G. Schrenk, Volker Schmidt, Herbert G. Sayer, Inken Hilgendorf, Andreas Hochhaus & Sebastian Scholl. (2016) Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment. Journal of Cancer Research and Clinical Oncology 143:2, pages 337-345.
Crossref
Crossref
Christoph Röllig, Hubert Serve, Andreas Hüttmann, Richard Noppeney, Carsten Müller-Tidow, Utz Krug, Claudia D Baldus, Christian H Brandts, Volker Kunzmann, Hermann Einsele, Alwin Krämer, Kerstin Schäfer-Eckart, Andreas Neubauer, Andreas Burchert, Aristoteles Giagounidis, Stefan W Krause, Andreas Mackensen, Walter Aulitzky, Regina Herbst, Mathias Hänel, Alexander Kiani, Norbert Frickhofen, Johannes Kullmer, Ulrich Kaiser, Hartmut Link, Thomas Geer, Albert Reichle, Christian Junghanß, Roland Repp, Frank Heits, Heinz Dürk, Jana Hase, Ina-Maria Klut, Thomas Illmer, Martin Bornhäuser, Markus Schaich, Stefani Parmentier, Martin Görner, Christian Thiede, Malte von Bonin, Johannes Schetelig, Michael Kramer, Wolfgang E Berdel & Gerhard Ehninger. (2015) Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. The Lancet Oncology 16:16, pages 1691-1699.
Crossref
Crossref
Monica R. Muppidi, Scott Portwood, Elizabeth A. Griffiths, James E. Thompson, Laurie A. Ford, Craig W. Freyer, Meir Wetzler & Eunice S. Wang. (2015) Decitabine and Sorafenib Therapy in FLT-3 ITD-Mutant Acute Myeloid Leukemia. Clinical Lymphoma Myeloma and Leukemia 15, pages S73-S79.
Crossref
Crossref
Guiyun Song, Benigno C. Valdez, Yang Li, Yan Liu, Richard E. Champlin & Borje S. Andersson. (2014) Synergistic Cytotoxicity of Sorafenib with Busulfan and Nucleoside Analogs in Human FMS-like Tyrosine Kinase 3 Internal Tandem Duplications–Positive Acute Myeloid Leukemia Cells. Biology of Blood and Marrow Transplantation 20:11, pages 1687-1695.
Crossref
Crossref
Giulia Fontanelli, Melania Rocco, Francesco Caracciolo, Edoardo Benedetti, Gabriele Buda, Enrico Orciuolo, Giovanni Carulli, Sara Galimberti, Antonio Azzarà & Mario Petrini. (2014) Sorafenib As Monotherapy or in Association With Cytarabine and Clofarabine for the Treatment of Relapsed/Refractory FLT3 ITD-Positive Advanced Acute Myeloid Leukemia. Clinical Lymphoma Myeloma and Leukemia 14:1, pages e13-e17.
Crossref
Crossref
Jens Hasskarl. 2014. Small Molecules in Oncology. Small Molecules in Oncology
145
164
.
Denise Wolleschak, Enrico Schalk, Christian Krogel, Tina M Schnoeder, Helga Luehr, Kathleen Jentsch-Ullrich, Thomas Fischer & Florian H Heidel. (2013) Rapid induction of complete molecular remission by sequential therapy with LDAC and sorafenib in FLT3-ITD-positive patients unfit for intensive treatment: two cases and review of the literature. Journal of Hematology & Oncology 6:1.
Crossref
Crossref
Parwathy Chandran, Neha Gupta, Archana Payickattu Retnakumari, Giridharan Loghanathan Malarvizhi, Pavithran Keechilat, Shantikumar Nair & Manzoor Koyakutty. (2013) Simultaneous inhibition of aberrant cancer kinome using rationally designed polymer-protein core-shell nanomedicine. Nanomedicine: Nanotechnology, Biology and Medicine 9:8, pages 1317-1327.
Crossref
Crossref
Sharyn D. Baker, Eric I. Zimmerman, Yong-Dong Wang, Shelley Orwick, Douglas S. Zatechka, Jassada Buaboonnam, Geoffrey A. Neale, Scott R. Olsen, Eric J. Enemark, Sheila Shurtleff, Jeffrey E. Rubnitz, Charles G. Mullighan & Hiroto Inaba. (2013) Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia. Clinical Cancer Research 19:20, pages 5758-5768.
Crossref
Crossref
Domenico Ribatti. (2013) Angiogenesis as a treatment target in leukemia. International Journal of Hematologic Oncology 2:3, pages 229-242.
Crossref
Crossref
Jerzy Hołowiecki & Aleksandra Hołowiecka. (2013) Leczenie celowane w ostrych białaczkach szpikowych. Acta Haematologica Polonica 44:2, pages 85-92.
Crossref
Crossref
R Wang, L Xia, J Gabrilove, S Waxman & Y Jing. (2012) Downregulation of Mcl-1 through GSK-3β activation contributes to arsenic trioxide-induced apoptosis in acute myeloid leukemia cells. Leukemia 27:2, pages 315-324.
Crossref
Crossref
S K Metzelder, T Schroeder, A Finck, S Scholl, M Fey, K Götze, Y C Linn, M Kröger, A Reiter, H R Salih, T Heinicke, R Stuhlmann, L Müller, A Giagounidis, R G Meyer, W Brugger, M Vöhringer, P Dreger, M Mori, N Basara, K Schäfer-Eckart, B Schultheis, C Baldus, A Neubauer & A Burchert. (2012) High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses. Leukemia 26:11, pages 2353-2359.
Crossref
Crossref